It’s perhaps the biggest twist in the tale to the Entresto (sacubitril/valsartan) patents saga in India and things don’t appear over yet.
Just as several Indian firms appeared to be cruising towards the launch of cut-price versions of Novartis AG’s blockbuster...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?